provitro AG Charitéplatz 1 tel +49.30.450 578 352 office@provitro.de
Charité Campus Mitte 10117 Berlin fax +49.30.450 578 952 www.provitro.de

provitro

Human Tissue Microarray - iCon (internal control) TMA® MUC-1

REF / Cat.-No.: 401 5222 Lot: 121iC

Label	Tissue type control tissue: mamma-carcinoma
● ● ● ● 1 2 3 4	spot 1: strong positive spot 2: moderate spot 3: moderate spot 4: negative
Free Space for your tissue under investigation	

Technical Information:

- Spot diameter: 1.5 mm
- Paraffin embedded tissue
- Fixation in 4 % paraformaldehyde in PBS
- Slide Material: Standard: Superfrost® Plus.

For Handling Instruction please see our iCon® TMA Product Sheet or contact our customer service.

Antibody / Marker description:

This gene is a member of the mucin family and encodes a membrane bound, glycosylated phosphoprotein. The protein is anchored to the apical surface of many epithelia by a transmembrane domain (EMA-epithelial membrane antigen), with the degree of glycosylation varying with cell type. It also includes a 20 aa variable number tandem repeat (VNTR) domain, with the number of repeats varying from 20 to 120 in different individuals. The protein serves a protective function by binding to pathogens and also functions in a cell signaling capacity. Overexpression, aberrant intracellular localization, and changes in glycosylation of this protein have been associated with carcinomas. Multiple alternatively spliced transcript variants that encode different isoforms of this gene have been reported, but the full-length nature of only some has been determined.

Literature:

- Peterson JA, Scallan CD, Ceriani RL, Hamosh M (2002). "Structural and functional aspects of three major glycoproteins of the human milk fat globule membrane.". *Adv. Exp. Med. Biol.* **501**: 179-87
- Leroy X, Buisine MP, Leteurtre E, *et al.* (2007). "[MUC1 (EMA): A key molecule of carcinogenesis?]". *Annales de pathologie* **26** (4): 257-66.
- Li Y, Cozzi PJ (2007). "MUC1 is a promising therapeutic target for prostate cancer therapy". *Current cancer drug targets* **7** (3): 259-71
- Leroy X, Buisine MP, Leteurtre E, *et al.* (2007). "[MUC1 (EMA): A key molecule of carcinogenesis?]". *Annales de pathologie* **26** (4): 257-66
- Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA (2006). "International Union of Pharmacology. LXIV. Estrogen receptors". *Pharmacol. Rev.* **58** (4): 773–81.
- Deroo BJ, Korach KS (2006). "Estrogen receptors and human disease". *J. Clin. Invest.* **116** (3): 561–70.
- Fabian CJ, Kimler BF (2005). "Selective estrogen-receptor modulators for primary prevention of breast cancer". *J. Clin. Oncol.* **23** (8): 1644–55.
- Ascenzi P, Bocedi A, Marino M (August 2006). "Structure-function relationship of estrogen receptor alpha and beta: impact on human health". *Mol Aspects Med* **27** (4): 299–402.
- Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith JC (2003). "Evaluation of an estrogen receptor-beta agonist in animal models of human disease". *Endocrinology* **144** (10): 4241–9

FOR INTERNAL QUALITY CONTROL . RESEARCH USE ONLY.